COVID-19 vaccines: MEPs quiz top officials on authorisation and contracts | Nieuws | Europees Parlement

 

COVID-19 vaccines: MEPs quiz top officials on authorisation and contracts 

Persbericht 
 
 
  • EMA Executive Director Cooke was questioned on evaluation and authorisation of vaccines 
  • Commission Director-General for Health Gallina updated MEPs on advanced purchase of vaccines 
  • MEPs want to scrutinise the effectiveness of EU’s approval system and soundness of financial management 

On Tuesday, MEPs quizzed the European Commission and European Medicines Agency on latest developments concerning the authorisation and purchase of COVID-19 vaccines.

Emer Cooke, Executive Director of the European Medicines Agency (EMA) updated Members of the Environment, Public Health and Food Safety (ENVI) Committee on the latest developments regarding the evaluation and authorisation of COVID-19 vaccines in the EU.


During the debate, MEPs asked about the timeframe of future approvals of vaccines, the results of monitoring the long-term efficacy of existing vaccines, as well as the recent investigation linked to the AstraZeneca vaccine. MEPs expressed their concerns regarding the slow rollout in the member states, and quizzed the EMA on the status of approving new EU manufacturing sites and maximising the use of vaccines doses.


In her answers, Emer Cooke reassured MEPs that the EU has in place a continuous control system to ensure that vaccines are safe and effective. She underlined the importance of communicating transparently to the EU public and building trust in scientific advice. She also reiterated the EMA’s commitment to applying the same standards in the authorisation of vaccines, irrespective of their origin.


Transparency of contracts


Sandra Gallina, the Commission’s Director-General for Health and Food Safety (SANTE), was quizzed by Members of the Budgetary Control Committee (CONT) on the eight advanced purchase agreements (APA) on vaccines concluded by the Commission with pharmaceutical companies.


MEPs questioned Ms Gallina on whether pharmaceutical companies are delivering on the contracts, the possible advantages of patent liberalisation, distribution of doses, fake vaccines available in the market, and making the cost of vaccines transparent. MEPs also raised the controversial issue of the contract with AstraZeneca. The Director-General confirmed that the company has not even delivered a quarter of the vaccines agreed in advance with the EU. She also committed to use all means available to reverse this situation.


You can watch both debates again via the link below


ENVI debate with EMA - opening remarks


ENVI debate with EMA - Q&A


ENVI debate with EMA - closing remarks


CONT debate with European Commission - opening remarks


CONT debate with European Commission - Q&A


CONT debate with European Commission - closing remarks


ENVI & CONT debates summary


 
  • Direct naar de inhoud van de pagina (druk op "Enter")
  • Direct naar de inhoud van de pagina (druk op "Enter")Direct naar de inhoud van de pagina (druk op "Enter")
  • Rechtstreeks naar talenmenu (druk op "Enter")
  • Rechtstreeks naar talenmenu (druk op "Enter")Rechtstreeks naar talenmenu (druk op "Enter")
  • Rechtstreeks naar zoekmenu (druk op "Enter")
  • Rechtstreeks naar zoekmenu (druk op "Enter")Rechtstreeks naar zoekmenu (druk op "Enter")
  • BG - български
  • BG - български BG - българскиBG - български
  • ES - español
  • ES - español ES - españolES - español
  • CS - čeština
  • CS - čeština CS - češtinaCS - čeština
  • DA - dansk
  • DA - dansk DA - danskDA - dansk
  • DE - Deutsch
  • DE - Deutsch DE - DeutschDE - Deutsch
  • ET - eesti keel
  • ET - eesti keel ET - eesti keelET - eesti keel
  • EL - ελληνικά
  • EL - ελληνικά EL - ελληνικάEL - ελληνικά
  • EN - English
  • EN - English EN - EnglishEN - English
  • FR - français
  • FR - français FR - françaisFR - français
  • GA - Gaeilge
  • GA - Gaeilge GA - GaeilgeGA - Gaeilge
  • HR - hrvatski
  • HR - hrvatski HR - hrvatskiHR - hrvatski
  • IT - italiano
  • IT - italiano IT - italianoIT - italiano
  • LV - latviešu valoda
  • LV - latviešu valoda LV - latviešu valodaLV - latviešu valoda
  • LT - lietuvių kalba
  • LT - lietuvių kalba LT - lietuvių kalbaLT - lietuvių kalba
  • HU - magyar
  • HU - magyar HU - magyarHU - magyar
  • MT - Malti
  • MT - Malti MT - MaltiMT - Malti
  • NL - Nederlands
  • NL - Nederlands NL - NederlandsNL - Nederlands
  • PL - polski
  • PL - polski PL - polskiPL - polski
  • PT - português
  • PT - português PT - portuguêsPT - português
  • RO - română
  • RO - română RO - românăRO - română
  • SK - slovenčina
  • SK - slovenčina SK - slovenčinaSK - slovenčina
  • SL - slovenščina
  • SL - slovenščina SL - slovenščinaSL - slovenščina
  • FI - suomi
  • FI - suomi FI - suomiFI - suomi
  • SV - svenska
  • SV - svenska SV - svenskaSV - svenska
  • Naar pagina gaan Nieuws
  • Naar pagina gaan Nieuws Naar pagina gaan Nieuws Naar pagina gaanNieuws
  • Naar pagina gaan Leden
  • Naar pagina gaan Leden Naar pagina gaan Leden Naar pagina gaanLeden
  • Naar pagina gaan Over het Parlement
  • Naar pagina gaan Over het Parlement Naar pagina gaan Over het Parlement Naar pagina gaanOver het Parlement
  • Naar pagina gaan Plenaire vergadering
  • Naar pagina gaan Plenaire vergadering Naar pagina gaan Plenaire vergadering Naar pagina gaanPlenaire vergadering
  • Naar pagina gaan Commissies
  • Naar pagina gaan Commissies Naar pagina gaan Commissies Naar pagina gaanCommissies
  • Naar pagina gaan Delegaties
  • Naar pagina gaan Delegaties Naar pagina gaan Delegaties Naar pagina gaanDelegaties
  • Andere websites Andere websites
  • Naar pagina gaan Multimedia Centre
  • Naar pagina gaan Multimedia Centre Naar pagina gaan Multimedia Centre Naar pagina gaanMultimedia Centre
  • Naar pagina gaan Webpagina van de Voorzitter
  • Naar pagina gaan Webpagina van de Voorzitter Naar pagina gaan Webpagina van de Voorzitter Naar pagina gaanWebpagina van de Voorzitter
  • Naar pagina gaan Secretariaat-generaal
  • Naar pagina gaan Secretariaat-generaal Naar pagina gaan Secretariaat-generaal Naar pagina gaanSecretariaat-generaal
  • Naar pagina gaan Think tank
  • Naar pagina gaan Think tank Naar pagina gaan Think tank Naar pagina gaanThink tank
  • Naar pagina gaan EP Newshub
  • Naar pagina gaan EP Newshub Naar pagina gaan EP Newshub Naar pagina gaanEP Newshub
  • Naar pagina gaan Tot uw dienst
  • Naar pagina gaan Tot uw dienst Naar pagina gaan Tot uw dienst Naar pagina gaanTot uw dienst
  • Naar pagina gaan Bezoeken
  • Naar pagina gaan Bezoeken Naar pagina gaan Bezoeken Naar pagina gaanBezoeken
  • Naar pagina gaan Legislative train
  • Naar pagina gaan Legislative train Naar pagina gaan Legislative train Naar pagina gaanLegislative train
  • Naar pagina gaan Contracten en subsidies
  • Naar pagina gaan Contracten en subsidies Naar pagina gaan Contracten en subsidies Naar pagina gaanContracten en subsidies
  • Naar pagina gaan Registreren
  • Naar pagina gaan Registreren Naar pagina gaan Registreren Naar pagina gaanRegistreren
    Nieuws Europees Parlement NieuwsNieuws Europees Parlement Europees Parlement Menu Menu
  • Nieuws
  • Nieuws Nieuws Nieuws
  • Naar pagina gaan Startpagina
  • Naar pagina gaan Startpagina Naar pagina gaan Startpagina Naar pagina gaanStartpagina
  • Naar pagina gaan Europese zaken
  • Naar pagina gaan Europese zaken Naar pagina gaan Europese zaken Naar pagina gaanEuropese zaken
  • Naar pagina gaan Wereld
  • Naar pagina gaan Wereld Naar pagina gaan Wereld Naar pagina gaanWereld
  • Naar pagina gaan Economie
  • Naar pagina gaan Economie Naar pagina gaan Economie Naar pagina gaanEconomie
  • Naar pagina gaan Maatschappij
  • Naar pagina gaan Maatschappij Naar pagina gaan Maatschappij Naar pagina gaanMaatschappij
  • Naar pagina gaan Veiligheid
  • Naar pagina gaan Veiligheid Naar pagina gaan Veiligheid Naar pagina gaanVeiligheid
  • Pers
  • Pers Pers Pers
  • Naar pagina gaan Startpagina
  • Naar pagina gaan Startpagina Naar pagina gaan Startpagina Naar pagina gaanStartpagina
  • Naar pagina gaan Accreditatie
  • Naar pagina gaan Accreditatie Naar pagina gaan Accreditatie Naar pagina gaanAccreditatie
  • Naar pagina gaan Contact
  • Naar pagina gaan Contact Naar pagina gaan Contact Naar pagina gaanContact
  • Agenda
  • Agenda Agenda Agenda
  • Naar pagina gaan Hoogtepunten
  • Naar pagina gaan Hoogtepunten Naar pagina gaan Hoogtepunten Naar pagina gaanHoogtepunten
  • Naar pagina gaan Wekelijkse agenda
  • Naar pagina gaan Wekelijkse agenda Naar pagina gaan Wekelijkse agenda Naar pagina gaanWekelijkse agenda
  • Naar pagina gaan Briefing
  • Naar pagina gaan Briefing Naar pagina gaan Briefing Naar pagina gaanBriefing
  • Veelgestelde vragen
  • Veelgestelde vragen Veelgestelde vragen Veelgestelde vragen
  • #EuropeanenTegenCovid19
  • #EuropeanenTegenCovid19 #EuropeanenTegenCovid19 #EuropeanenTegenCovid19Naar het zoekveld
    Zoekopdracht starten Europees Parlement
    Pers   > Huidige pagina: COVID-19 vaccines: MEPs quiz top officials on authorisation and contracts  
    Pers   > Pers  Pers > Huidige pagina: COVID-19 vaccines: MEPs quiz top officials on authorisation and contracts   Huidige pagina: COVID-19 vaccines: MEPs quiz top officials on authorisation and contracts   Huidige pagina:COVID-19 vaccines: MEPs quiz top officials on authorisation and contracts  Pers  Pers >
     

    COVID-19 vaccines: MEPs quiz top officials on authorisation and contracts 

    Persbericht 
     
     
    • EMA Executive Director Cooke was questioned on evaluation and authorisation of vaccines 
    • Commission Director-General for Health Gallina updated MEPs on advanced purchase of vaccines 
    • MEPs want to scrutinise the effectiveness of EU’s approval system and soundness of financial management 

    On Tuesday, MEPs quizzed the European Commission and European Medicines Agency on latest developments concerning the authorisation and purchase of COVID-19 vaccines.

    Emer Cooke, Executive Director of the European Medicines Agency (EMA) updated Members of the Environment, Public Health and Food Safety (ENVI) Committee on the latest developments regarding the evaluation and authorisation of COVID-19 vaccines in the EU.


    During the debate, MEPs asked about the timeframe of future approvals of vaccines, the results of monitoring the long-term efficacy of existing vaccines, as well as the recent investigation linked to the AstraZeneca vaccine. MEPs expressed their concerns regarding the slow rollout in the member states, and quizzed the EMA on the status of approving new EU manufacturing sites and maximising the use of vaccines doses.


    In her answers, Emer Cooke reassured MEPs that the EU has in place a continuous control system to ensure that vaccines are safe and effective. She underlined the importance of communicating transparently to the EU public and building trust in scientific advice. She also reiterated the EMA’s commitment to applying the same standards in the authorisation of vaccines, irrespective of their origin.


    Transparency of contracts


    Sandra Gallina, the Commission’s Director-General for Health and Food Safety (SANTE), was quizzed by Members of the Budgetary Control Committee (CONT) on the eight advanced purchase agreements (APA) on vaccines concluded by the Commission with pharmaceutical companies.


    MEPs questioned Ms Gallina on whether pharmaceutical companies are delivering on the contracts, the possible advantages of patent liberalisation, distribution of doses, fake vaccines available in the market, and making the cost of vaccines transparent. MEPs also raised the controversial issue of the contract with AstraZeneca. The Director-General confirmed that the company has not even delivered a quarter of the vaccines agreed in advance with the EU. She also committed to use all means available to reverse this situation.


    You can watch both debates again via the link below


    ENVI debate with EMA - opening remarks


    ENVI debate with EMA - Q&A


    ENVI debate with EMA - closing remarks


    CONT debate with European Commission - opening remarks


    CONT debate with European Commission - Q&A


    CONT debate with European Commission - closing remarks


    ENVI & CONT debates summary


     
     

    COVID-19 vaccines: MEPs quiz top officials on authorisation and contracts 

    Persbericht 
     
     

    COVID-19 vaccines: MEPs quiz top officials on authorisation and contracts 

    Persbericht 
     
     
     

    COVID-19 vaccines: MEPs quiz top officials on authorisation and contracts 

    Persbericht 
     

    COVID-19 vaccines: MEPs quiz top officials on authorisation and contracts 

    Persbericht 
     

    COVID-19 vaccines: MEPs quiz top officials on authorisation and contracts 

    Persbericht 
     

    COVID-19 vaccines: MEPs quiz top officials on authorisation and contracts 

    COVID-19 vaccines: MEPs quiz top officials on authorisation and contracts 
    COVID-19 vaccines: MEPs quiz top officials on authorisation and contracts 
    Persbericht 
     
    Persbericht 
    Persbericht  CONT  CONTCONT  ENVI  ENVIENVI 
     
     
     
    • EMA Executive Director Cooke was questioned on evaluation and authorisation of vaccines 
    • Commission Director-General for Health Gallina updated MEPs on advanced purchase of vaccines 
    • MEPs want to scrutinise the effectiveness of EU’s approval system and soundness of financial management 

    On Tuesday, MEPs quizzed the European Commission and European Medicines Agency on latest developments concerning the authorisation and purchase of COVID-19 vaccines.

    Emer Cooke, Executive Director of the European Medicines Agency (EMA) updated Members of the Environment, Public Health and Food Safety (ENVI) Committee on the latest developments regarding the evaluation and authorisation of COVID-19 vaccines in the EU.


    During the debate, MEPs asked about the timeframe of future approvals of vaccines, the results of monitoring the long-term efficacy of existing vaccines, as well as the recent investigation linked to the AstraZeneca vaccine. MEPs expressed their concerns regarding the slow rollout in the member states, and quizzed the EMA on the status of approving new EU manufacturing sites and maximising the use of vaccines doses.


    In her answers, Emer Cooke reassured MEPs that the EU has in place a continuous control system to ensure that vaccines are safe and effective. She underlined the importance of communicating transparently to the EU public and building trust in scientific advice. She also reiterated the EMA’s commitment to applying the same standards in the authorisation of vaccines, irrespective of their origin.


    Transparency of contracts


    Sandra Gallina, the Commission’s Director-General for Health and Food Safety (SANTE), was quizzed by Members of the Budgetary Control Committee (CONT) on the eight advanced purchase agreements (APA) on vaccines concluded by the Commission with pharmaceutical companies.


    MEPs questioned Ms Gallina on whether pharmaceutical companies are delivering on the contracts, the possible advantages of patent liberalisation, distribution of doses, fake vaccines available in the market, and making the cost of vaccines transparent. MEPs also raised the controversial issue of the contract with AstraZeneca. The Director-General confirmed that the company has not even delivered a quarter of the vaccines agreed in advance with the EU. She also committed to use all means available to reverse this situation.


    You can watch both debates again via the link below


    ENVI debate with EMA - opening remarks


    ENVI debate with EMA - Q&A


    ENVI debate with EMA - closing remarks


    CONT debate with European Commission - opening remarks


    CONT debate with European Commission - Q&A


    CONT debate with European Commission - closing remarks


    ENVI & CONT debates summary


     
     
    • EMA Executive Director Cooke was questioned on evaluation and authorisation of vaccines 
    • Commission Director-General for Health Gallina updated MEPs on advanced purchase of vaccines 
    • MEPs want to scrutinise the effectiveness of EU’s approval system and soundness of financial management 

    On Tuesday, MEPs quizzed the European Commission and European Medicines Agency on latest developments concerning the authorisation and purchase of COVID-19 vaccines.

    Emer Cooke, Executive Director of the European Medicines Agency (EMA) updated Members of the Environment, Public Health and Food Safety (ENVI) Committee on the latest developments regarding the evaluation and authorisation of COVID-19 vaccines in the EU.


    During the debate, MEPs asked about the timeframe of future approvals of vaccines, the results of monitoring the long-term efficacy of existing vaccines, as well as the recent investigation linked to the AstraZeneca vaccine. MEPs expressed their concerns regarding the slow rollout in the member states, and quizzed the EMA on the status of approving new EU manufacturing sites and maximising the use of vaccines doses.


    In her answers, Emer Cooke reassured MEPs that the EU has in place a continuous control system to ensure that vaccines are safe and effective. She underlined the importance of communicating transparently to the EU public and building trust in scientific advice. She also reiterated the EMA’s commitment to applying the same standards in the authorisation of vaccines, irrespective of their origin.


    Transparency of contracts


    Sandra Gallina, the Commission’s Director-General for Health and Food Safety (SANTE), was quizzed by Members of the Budgetary Control Committee (CONT) on the eight advanced purchase agreements (APA) on vaccines concluded by the Commission with pharmaceutical companies.


    MEPs questioned Ms Gallina on whether pharmaceutical companies are delivering on the contracts, the possible advantages of patent liberalisation, distribution of doses, fake vaccines available in the market, and making the cost of vaccines transparent. MEPs also raised the controversial issue of the contract with AstraZeneca. The Director-General confirmed that the company has not even delivered a quarter of the vaccines agreed in advance with the EU. She also committed to use all means available to reverse this situation.


    You can watch both debates again via the link below


    ENVI debate with EMA - opening remarks


    ENVI debate with EMA - Q&A


    ENVI debate with EMA - closing remarks


    CONT debate with European Commission - opening remarks


    CONT debate with European Commission - Q&A


    CONT debate with European Commission - closing remarks


    ENVI & CONT debates summary


     
     
     

    Deel deze pagina: 

    Deel deze pagina: 
    Deel deze pagina: 
  • Facebook Facebook 
  • Twitter Twitter 
  • LinkedIn LinkedIn 
  • Whatsapp Whatsapp 
    • EMA Executive Director Cooke was questioned on evaluation and authorisation of vaccines 
    • Commission Director-General for Health Gallina updated MEPs on advanced purchase of vaccines 
    • MEPs want to scrutinise the effectiveness of EU’s approval system and soundness of financial management 

    On Tuesday, MEPs quizzed the European Commission and European Medicines Agency on latest developments concerning the authorisation and purchase of COVID-19 vaccines.

    Emer Cooke, Executive Director of the European Medicines Agency (EMA) updated Members of the Environment, Public Health and Food Safety (ENVI) Committee on the latest developments regarding the evaluation and authorisation of COVID-19 vaccines in the EU.


    During the debate, MEPs asked about the timeframe of future approvals of vaccines, the results of monitoring the long-term efficacy of existing vaccines, as well as the recent investigation linked to the AstraZeneca vaccine. MEPs expressed their concerns regarding the slow rollout in the member states, and quizzed the EMA on the status of approving new EU manufacturing sites and maximising the use of vaccines doses.


    In her answers, Emer Cooke reassured MEPs that the EU has in place a continuous control system to ensure that vaccines are safe and effective. She underlined the importance of communicating transparently to the EU public and building trust in scientific advice. She also reiterated the EMA’s commitment to applying the same standards in the authorisation of vaccines, irrespective of their origin.


    Transparency of contracts


    Sandra Gallina, the Commission’s Director-General for Health and Food Safety (SANTE), was quizzed by Members of the Budgetary Control Committee (CONT) on the eight advanced purchase agreements (APA) on vaccines concluded by the Commission with pharmaceutical companies.


    MEPs questioned Ms Gallina on whether pharmaceutical companies are delivering on the contracts, the possible advantages of patent liberalisation, distribution of doses, fake vaccines available in the market, and making the cost of vaccines transparent. MEPs also raised the controversial issue of the contract with AstraZeneca. The Director-General confirmed that the company has not even delivered a quarter of the vaccines agreed in advance with the EU. She also committed to use all means available to reverse this situation.


    You can watch both debates again via the link below


    ENVI debate with EMA - opening remarks


    ENVI debate with EMA - Q&A


    ENVI debate with EMA - closing remarks


    CONT debate with European Commission - opening remarks


    CONT debate with European Commission - Q&A


    CONT debate with European Commission - closing remarks


    ENVI & CONT debates summary


    • EMA Executive Director Cooke was questioned on evaluation and authorisation of vaccines 
    • Commission Director-General for Health Gallina updated MEPs on advanced purchase of vaccines 
    • MEPs want to scrutinise the effectiveness of EU’s approval system and soundness of financial management 

    On Tuesday, MEPs quizzed the European Commission and European Medicines Agency on latest developments concerning the authorisation and purchase of COVID-19 vaccines.

    Emer Cooke, Executive Director of the European Medicines Agency (EMA) updated Members of the Environment, Public Health and Food Safety (ENVI) Committee on the latest developments regarding the evaluation and authorisation of COVID-19 vaccines in the EU.


    During the debate, MEPs asked about the timeframe of future approvals of vaccines, the results of monitoring the long-term efficacy of existing vaccines, as well as the recent investigation linked to the AstraZeneca vaccine. MEPs expressed their concerns regarding the slow rollout in the member states, and quizzed the EMA on the status of approving new EU manufacturing sites and maximising the use of vaccines doses.


    In her answers, Emer Cooke reassured MEPs that the EU has in place a continuous control system to ensure that vaccines are safe and effective. She underlined the importance of communicating transparently to the EU public and building trust in scientific advice. She also reiterated the EMA’s commitment to applying the same standards in the authorisation of vaccines, irrespective of their origin.


    Transparency of contracts


    Sandra Gallina, the Commission’s Director-General for Health and Food Safety (SANTE), was quizzed by Members of the Budgetary Control Committee (CONT) on the eight advanced purchase agreements (APA) on vaccines concluded by the Commission with pharmaceutical companies.


    MEPs questioned Ms Gallina on whether pharmaceutical companies are delivering on the contracts, the possible advantages of patent liberalisation, distribution of doses, fake vaccines available in the market, and making the cost of vaccines transparent. MEPs also raised the controversial issue of the contract with AstraZeneca. The Director-General confirmed that the company has not even delivered a quarter of the vaccines agreed in advance with the EU. She also committed to use all means available to reverse this situation.


    You can watch both debates again via the link below


    ENVI debate with EMA - opening remarks


    ENVI debate with EMA - Q&A


    ENVI debate with EMA - closing remarks


    CONT debate with European Commission - opening remarks


    CONT debate with European Commission - Q&A


    CONT debate with European Commission - closing remarks


    ENVI & CONT debates summary


    • EMA Executive Director Cooke was questioned on evaluation and authorisation of vaccines 
    • Commission Director-General for Health Gallina updated MEPs on advanced purchase of vaccines 
    • MEPs want to scrutinise the effectiveness of EU’s approval system and soundness of financial management 

    On Tuesday, MEPs quizzed the European Commission and European Medicines Agency on latest developments concerning the authorisation and purchase of COVID-19 vaccines.

    Emer Cooke, Executive Director of the European Medicines Agency (EMA) updated Members of the Environment, Public Health and Food Safety (ENVI) Committee on the latest developments regarding the evaluation and authorisation of COVID-19 vaccines in the EU.


    During the debate, MEPs asked about the timeframe of future approvals of vaccines, the results of monitoring the long-term efficacy of existing vaccines, as well as the recent investigation linked to the AstraZeneca vaccine. MEPs expressed their concerns regarding the slow rollout in the member states, and quizzed the EMA on the status of approving new EU manufacturing sites and maximising the use of vaccines doses.


    In her answers, Emer Cooke reassured MEPs that the EU has in place a continuous control system to ensure that vaccines are safe and effective. She underlined the importance of communicating transparently to the EU public and building trust in scientific advice. She also reiterated the EMA’s commitment to applying the same standards in the authorisation of vaccines, irrespective of their origin.


    Transparency of contracts


    Sandra Gallina, the Commission’s Director-General for Health and Food Safety (SANTE), was quizzed by Members of the Budgetary Control Committee (CONT) on the eight advanced purchase agreements (APA) on vaccines concluded by the Commission with pharmaceutical companies.


    MEPs questioned Ms Gallina on whether pharmaceutical companies are delivering on the contracts, the possible advantages of patent liberalisation, distribution of doses, fake vaccines available in the market, and making the cost of vaccines transparent. MEPs also raised the controversial issue of the contract with AstraZeneca. The Director-General confirmed that the company has not even delivered a quarter of the vaccines agreed in advance with the EU. She also committed to use all means available to reverse this situation.


    You can watch both debates again via the link below


    ENVI debate with EMA - opening remarks


    ENVI debate with EMA - Q&A


    ENVI debate with EMA - closing remarks


    CONT debate with European Commission - opening remarks


    CONT debate with European Commission - Q&A


    CONT debate with European Commission - closing remarks


    ENVI & CONT debates summary


    • EMA Executive Director Cooke was questioned on evaluation and authorisation of vaccines 
    • Commission Director-General for Health Gallina updated MEPs on advanced purchase of vaccines 
    • MEPs want to scrutinise the effectiveness of EU’s approval system and soundness of financial management 
    • EMA Executive Director Cooke was questioned on evaluation and authorisation of vaccines 
    • Commission Director-General for Health Gallina updated MEPs on advanced purchase of vaccines 
    • MEPs want to scrutinise the effectiveness of EU’s approval system and soundness of financial management 
    • EMA Executive Director Cooke was questioned on evaluation and authorisation of vaccines 
    • Commission Director-General for Health Gallina updated MEPs on advanced purchase of vaccines 
    • MEPs want to scrutinise the effectiveness of EU’s approval system and soundness of financial management 
    • EMA Executive Director Cooke was questioned on evaluation and authorisation of vaccines 
    • Commission Director-General for Health Gallina updated MEPs on advanced purchase of vaccines 
    • MEPs want to scrutinise the effectiveness of EU’s approval system and soundness of financial management 
    • EMA Executive Director Cooke was questioned on evaluation and authorisation of vaccines 
    • Commission Director-General for Health Gallina updated MEPs on advanced purchase of vaccines 
    • MEPs want to scrutinise the effectiveness of EU’s approval system and soundness of financial management 
  • EMA Executive Director Cooke was questioned on evaluation and authorisation of vaccines 
  • EMA Executive Director Cooke was questioned on evaluation and authorisation of vaccines 
    EMA Executive Director Cooke was questioned on evaluation and authorisation of vaccines 
  • Commission Director-General for Health Gallina updated MEPs on advanced purchase of vaccines 
  • Commission Director-General for Health Gallina updated MEPs on advanced purchase of vaccines 
    Commission Director-General for Health Gallina updated MEPs on advanced purchase of vaccines 
  • MEPs want to scrutinise the effectiveness of EU’s approval system and soundness of financial management 
  • MEPs want to scrutinise the effectiveness of EU’s approval system and soundness of financial management 
    MEPs want to scrutinise the effectiveness of EU’s approval system and soundness of financial management 

    On Tuesday, MEPs quizzed the European Commission and European Medicines Agency on latest developments concerning the authorisation and purchase of COVID-19 vaccines.

    On Tuesday, MEPs quizzed the European Commission and European Medicines Agency on latest developments concerning the authorisation and purchase of COVID-19 vaccines.

    On Tuesday, MEPs quizzed the European Commission and European Medicines Agency on latest developments concerning the authorisation and purchase of COVID-19 vaccines.

    On Tuesday, MEPs quizzed the European Commission and European Medicines Agency on latest developments concerning the authorisation and purchase of COVID-19 vaccines.

    Emer Cooke, Executive Director of the European Medicines Agency (EMA) updated Members of the Environment, Public Health and Food Safety (ENVI) Committee on the latest developments regarding the evaluation and authorisation of COVID-19 vaccines in the EU.


    During the debate, MEPs asked about the timeframe of future approvals of vaccines, the results of monitoring the long-term efficacy of existing vaccines, as well as the recent investigation linked to the AstraZeneca vaccine. MEPs expressed their concerns regarding the slow rollout in the member states, and quizzed the EMA on the status of approving new EU manufacturing sites and maximising the use of vaccines doses.


    In her answers, Emer Cooke reassured MEPs that the EU has in place a continuous control system to ensure that vaccines are safe and effective. She underlined the importance of communicating transparently to the EU public and building trust in scientific advice. She also reiterated the EMA’s commitment to applying the same standards in the authorisation of vaccines, irrespective of their origin.


    Transparency of contracts


    Sandra Gallina, the Commission’s Director-General for Health and Food Safety (SANTE), was quizzed by Members of the Budgetary Control Committee (CONT) on the eight advanced purchase agreements (APA) on vaccines concluded by the Commission with pharmaceutical companies.


    MEPs questioned Ms Gallina on whether pharmaceutical companies are delivering on the contracts, the possible advantages of patent liberalisation, distribution of doses, fake vaccines available in the market, and making the cost of vaccines transparent. MEPs also raised the controversial issue of the contract with AstraZeneca. The Director-General confirmed that the company has not even delivered a quarter of the vaccines agreed in advance with the EU. She also committed to use all means available to reverse this situation.


    You can watch both debates again via the link below


    ENVI debate with EMA - opening remarks


    ENVI debate with EMA - Q&A


    ENVI debate with EMA - closing remarks


    CONT debate with European Commission - opening remarks


    CONT debate with European Commission - Q&A


    CONT debate with European Commission - closing remarks


    ENVI & CONT debates summary


    Emer Cooke, Executive Director of the European Medicines Agency (EMA) updated Members of the Environment, Public Health and Food Safety (ENVI) Committee on the latest developments regarding the evaluation and authorisation of COVID-19 vaccines in the EU.


    During the debate, MEPs asked about the timeframe of future approvals of vaccines, the results of monitoring the long-term efficacy of existing vaccines, as well as the recent investigation linked to the AstraZeneca vaccine. MEPs expressed their concerns regarding the slow rollout in the member states, and quizzed the EMA on the status of approving new EU manufacturing sites and maximising the use of vaccines doses.


    In her answers, Emer Cooke reassured MEPs that the EU has in place a continuous control system to ensure that vaccines are safe and effective. She underlined the importance of communicating transparently to the EU public and building trust in scientific advice. She also reiterated the EMA’s commitment to applying the same standards in the authorisation of vaccines, irrespective of their origin.


    Transparency of contracts


    Sandra Gallina, the Commission’s Director-General for Health and Food Safety (SANTE), was quizzed by Members of the Budgetary Control Committee (CONT) on the eight advanced purchase agreements (APA) on vaccines concluded by the Commission with pharmaceutical companies.


    MEPs questioned Ms Gallina on whether pharmaceutical companies are delivering on the contracts, the possible advantages of patent liberalisation, distribution of doses, fake vaccines available in the market, and making the cost of vaccines transparent. MEPs also raised the controversial issue of the contract with AstraZeneca. The Director-General confirmed that the company has not even delivered a quarter of the vaccines agreed in advance with the EU. She also committed to use all means available to reverse this situation.


    You can watch both debates again via the link below


    ENVI debate with EMA - opening remarks


    ENVI debate with EMA - Q&A


    ENVI debate with EMA - closing remarks


    CONT debate with European Commission - opening remarks


    CONT debate with European Commission - Q&A


    CONT debate with European Commission - closing remarks


    ENVI & CONT debates summary


    Emer Cooke, Executive Director of the European Medicines Agency (EMA) updated Members of the Environment, Public Health and Food Safety (ENVI) Committee on the latest developments regarding the evaluation and authorisation of COVID-19 vaccines in the EU.


    During the debate, MEPs asked about the timeframe of future approvals of vaccines, the results of monitoring the long-term efficacy of existing vaccines, as well as the recent investigation linked to the AstraZeneca vaccine. MEPs expressed their concerns regarding the slow rollout in the member states, and quizzed the EMA on the status of approving new EU manufacturing sites and maximising the use of vaccines doses.


    In her answers, Emer Cooke reassured MEPs that the EU has in place a continuous control system to ensure that vaccines are safe and effective. She underlined the importance of communicating transparently to the EU public and building trust in scientific advice. She also reiterated the EMA’s commitment to applying the same standards in the authorisation of vaccines, irrespective of their origin.


    Transparency of contracts


    Sandra Gallina, the Commission’s Director-General for Health and Food Safety (SANTE), was quizzed by Members of the Budgetary Control Committee (CONT) on the eight advanced purchase agreements (APA) on vaccines concluded by the Commission with pharmaceutical companies.


    MEPs questioned Ms Gallina on whether pharmaceutical companies are delivering on the contracts, the possible advantages of patent liberalisation, distribution of doses, fake vaccines available in the market, and making the cost of vaccines transparent. MEPs also raised the controversial issue of the contract with AstraZeneca. The Director-General confirmed that the company has not even delivered a quarter of the vaccines agreed in advance with the EU. She also committed to use all means available to reverse this situation.


    You can watch both debates again via the link below


    ENVI debate with EMA - opening remarks


    ENVI debate with EMA - Q&A


    ENVI debate with EMA - closing remarks


    CONT debate with European Commission - opening remarks


    CONT debate with European Commission - Q&A


    CONT debate with European Commission - closing remarks


    ENVI & CONT debates summary


    Emer Cooke, Executive Director of the European Medicines Agency (EMA) updated Members of the Environment, Public Health and Food Safety (ENVI) Committee on the latest developments regarding the evaluation and authorisation of COVID-19 vaccines in the EU.

    European Medicines Agency

    During the debate, MEPs asked about the timeframe of future approvals of vaccines, the results of monitoring the long-term efficacy of existing vaccines, as well as the recent investigation linked to the AstraZeneca vaccine. MEPs expressed their concerns regarding the slow rollout in the member states, and quizzed the EMA on the status of approving new EU manufacturing sites and maximising the use of vaccines doses.


    In her answers, Emer Cooke reassured MEPs that the EU has in place a continuous control system to ensure that vaccines are safe and effective. She underlined the importance of communicating transparently to the EU public and building trust in scientific advice. She also reiterated the EMA’s commitment to applying the same standards in the authorisation of vaccines, irrespective of their origin.


    Transparency of contracts

    Transparency of contracts

    Sandra Gallina, the Commission’s Director-General for Health and Food Safety (SANTE), was quizzed by Members of the Budgetary Control Committee (CONT) on the eight advanced purchase agreements (APA) on vaccines concluded by the Commission with pharmaceutical companies.


    MEPs questioned Ms Gallina on whether pharmaceutical companies are delivering on the contracts, the possible advantages of patent liberalisation, distribution of doses, fake vaccines available in the market, and making the cost of vaccines transparent. MEPs also raised the controversial issue of the contract with AstraZeneca. The Director-General confirmed that the company has not even delivered a quarter of the vaccines agreed in advance with the EU. She also committed to use all means available to reverse this situation.


    You can watch both debates again via the link below

    You can watch both debates again via the link below

    ENVI debate with EMA - opening remarks

    ENVI debate with EMA - opening remarks

    ENVI debate with EMA - Q&A

    ENVI debate with EMA - Q&A

    ENVI debate with EMA - closing remarks

    ENVI debate with EMA - closing remarks

    CONT debate with European Commission - opening remarks

    CONT debate with European Commission - opening remarks

    CONT debate with European Commission - Q&A

    CONT debate with European Commission - Q&A

    CONT debate with European Commission - closing remarks

    CONT debate with European Commission - closing remarks

    ENVI & CONT debates summary

    ENVI & CONT debates summary

    Contact: 

    Contact: 
    Contact: 
  • Dana POPP 

    Dana POPP Dana POPP 
    Press Officer 
    Press Officer Press Officer 
    Contactgegevens: 
    Contactgegevens: 
  • Telefoonnummer: (+32) 2 28 46330 (BXL) 
  • Telefoonnummer: (+32) 2 28 46330 (BXL) Telefoonnummer: (+32) 2 28 46330 (BXL)Telefoonnummer: (BXL) 
  • Telefoonnummer: (+33) 3 881 74903 (STR) 
  • Telefoonnummer: (+33) 3 881 74903 (STR) Telefoonnummer: (+33) 3 881 74903 (STR)Telefoonnummer: (STR) 
  • Mobiel telefoonnummer: (+32) 470 95 17 07 
  • Mobiel telefoonnummer: (+32) 470 95 17 07 Mobiel telefoonnummer: (+32) 470 95 17 07Mobiel telefoonnummer:  
  • E-mail: dana.popp@europarl.europa.eu 
  • E-mail: dana.popp@europarl.europa.eu E-mail: dana.popp@europarl.europa.euE-mail:  
  • E-mail: envi-press@europarl.europa.eu 
  • E-mail: envi-press@europarl.europa.eu E-mail: envi-press@europarl.europa.euE-mail:  
  • Twitteraccount: @EP_Environment 
  • Twitteraccount: @EP_Environment Twitteraccount: @EP_EnvironmentTwitteraccount:  
  • Cezary LEWANOWICZ 

    Cezary LEWANOWICZ Cezary LEWANOWICZ 
    Press Officer 
    Press Officer Press Officer 
    Contactgegevens: 
    Contactgegevens: 
  • Telefoonnummer: (+32) 2 28 30297 (BXL) 
  • Telefoonnummer: (+32) 2 28 30297 (BXL) Telefoonnummer: (+32) 2 28 30297 (BXL)Telefoonnummer: (BXL) 
  • Telefoonnummer: (+33) 3 881 64407 (STR) 
  • Telefoonnummer: (+33) 3 881 64407 (STR) Telefoonnummer: (+33) 3 881 64407 (STR)Telefoonnummer: (STR) 
  • Mobiel telefoonnummer: (+32) 498 98 34 02 
  • Mobiel telefoonnummer: (+32) 498 98 34 02 Mobiel telefoonnummer: (+32) 498 98 34 02Mobiel telefoonnummer:  
  • E-mail: cezary.lewanowicz@europarl.europa.eu 
  • E-mail: cezary.lewanowicz@europarl.europa.eu E-mail: cezary.lewanowicz@europarl.europa.euE-mail:  
  • E-mail: cont-press@europarl.europa.eu 
  • E-mail: cont-press@europarl.europa.eu E-mail: cont-press@europarl.europa.euE-mail:  
  • Twitteraccount: @EP_BudgControl 
  • Twitteraccount: @EP_BudgControl Twitteraccount: @EP_BudgControlTwitteraccount:  
     
     

    Further information 

    Further information 
    Further information 
  • Committee on Budgetary Control  Committee on Budgetary Control 
  • Committee on the Environment, Public Health and Food Safety  Committee on the Environment, Public Health and Food Safety 
  • EU vaccination strategy  EU vaccination strategy 
  • EU COVID-19 vaccines portfolio (European Commission)   EU COVID-19 vaccines portfolio (European Commission)  
  • Free photos, video and audio material related to EU vaccines strategy   Free photos, video and audio material related to EU vaccines strategy  
     
     
     
     
     

    Productinformatie 

    REF.:  20210322IPR00504 

    Productinformatie 

    Productinformatie 
    Productinformatie 
    Productinformatie 
    REF.:  20210322IPR00504 
    REF.:  20210322IPR00504 
    REF.: REF.:REF.: 20210322IPR00504 20210322IPR00504 

    Deel deze pagina: 

    Deel deze pagina: 
    Deel deze pagina: 
  • Facebook Facebook 
  • Twitter Twitter 
  • LinkedIn LinkedIn 
  • Whatsapp Whatsapp Aanmelden voor e-mailupdatesAanmelden voor e-mailupdatesPdf-versie Pdf-versie 

    Voettekst 

    Voettekst Nieuws  Bekijk het menu: nieuws  Bekijk het menu: nieuws 
    Het Parlement in uw land 
  • Brussels  
  • Brussels   Brussels 
  • Den Haag  
  • Den Haag   Den Haag Tools 
  • Wetgevingsobservatorium  
  • Wetgevingsobservatorium   Wetgevingsobservatorium 
  • Multimedia Centre  
  • Multimedia Centre   Multimedia Centre 
  • EbS  
  • EbS   EbS 
    De Voorzitter van het Europees Parlement 
  • Webpagina van de Voorzitter van het Parlement  
  • Webpagina van de Voorzitter van het Parlement   Webpagina van de Voorzitter van het Parlement  Menu verbergen: Nieuws   Menu verbergen: Nieuws Europees Parlement  Menu bekijken: Europees Parlement   Menu bekijken: Europees Parlement 
  • Nieuws 
  • Nieuws  Nieuws 
  • Leden 
  • Leden  Leden 
  • Over het Parlement 
  • Over het Parlement  Over het Parlement 
  • Plenaire vergadering 
  • Plenaire vergadering  Plenaire vergadering 
  • Commissies 
  • Commissies  Commissies 
  • Delegaties 
  • Delegaties  Delegaties Menu verbergen: Europees Parlement Menu verbergen: Europees Parlement  

    Het Parlement in de sociale media  

    Het Parlement in de sociale media 
  • Facebook  
  • Facebook   Facebook 
  • Twitter  
  • Twitter   Twitter 
  • Facebook  
  • Facebook   Facebook 
  • LinkedIn  
  • LinkedIn   LinkedIn 
  • YouTube  
  • YouTube   YouTube 
  • Instagram  
  • Instagram   Instagram 
  • Pinterest  
  • Pinterest   Pinterest 
  • Snapchat  
  • Snapchat   Snapchat 
  • Reddit  
  • Reddit   Reddit Informatieve links 
  • Contact 
  • Contact Contact 
  • RSS 
  • RSS RSS 
  • Sitemap 
  • Sitemap Sitemap 
  • Juridische mededeling 
  • Juridische mededeling Juridische mededeling 
  • Privacybeleid 
  • Privacybeleid Privacybeleid 
  • Toegankelijkheid 
  • Toegankelijkheid Toegankelijkheid